Merck: promising results for pneumococcal vaccine

(CercleFinance.com) - Merck today announced the results of a Phase 3 trial evaluating V116, its investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults.


In adults aged 50+ (Cohort 1), V116 elicited non-inferior immune responses to PCV20 for the
10 serotypes common to both vaccines, as measured by serotype-specific geometric mean titers (GMTs) of opsonophagocyte activity (OPA) at day 30.

In adults aged 18 to 49 (Cohort 2), V116 elicited non-inferior (immunobridged) immune responses compared to adults aged 50 to 64, as assessed by serotype-specific AOP GMTs 30 days after vaccination.

In both cohorts, V116 had a comparable safety profile to PCV20.



Copyright (c) 2023 CercleFinance.com. All rights reserved.